WS
ESPR

Wedbush Securities’s Esperion Therapeutics ESPR Stock Holding History

Wedbush Securities’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,775
Closed -$309K – 740
2015
Q2 		$309K Buy
+3,775
New +$370K 0.06% 419

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wedbush Securities's ESPR Position: Q3 2015 in Review

Wedbush Securities sold out of Esperion Therapeutics (ESPR) in Q3 2015, closing a stake of 3,775 shares — an estimated $309K sold.

Wedbush Securities first reported a position in ESPR in Q2 2015 and held it in 1 quarter. The position peaked at $309K in Q2 2015. 121 funds tracked by Wall St. Rank hold ESPR as of Q3 2015.

  • Wedbush Securities reported no remaining Esperion Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Wedbush Securities sold 3,775 Esperion Therapeutics shares in Q3 2015, an estimated $309K.
  • Wedbush Securities first reported a position in Esperion Therapeutics in Q2 2015 and held it in 1 quarter.
  • Wedbush Securities's Esperion Therapeutics position peaked at $309K in Q2 2015.
  • 121 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2015.

Based on Wedbush Securities's 13F filing for Q3 2015, filed 28 Oct 2015.